Comparing SARC-CalF With SARC-F for Screening Sarcopenia in Adults With Type 2 Diabetes Mellitus

Zeru Xu1, Ping Zhang2, Yifei Chen3, Jiahong Jiang1, Zijun Zhou1 and Hong Zhu1*.

1 Department of Endocrinology and Metabolism, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, 2 Department of Endocrinology, The Second People’s Hospital of Xining, Xining, China, 3 Department of Medicine, Changsha Medical University, Changsha, China

Background: The prevalence of sarcopenia is high in older people with type 2 diabetes mellitus (T2DM) and is now considered a critical problem in the healthcare sector. However, the preferred screening tool for identifying sarcopenia remains unknown. Thus, the aim of this study was to ensure that the diagnostic values of the SARC-F (strength, assisting with walking, rising from a chair, climbing stairs, and falling) and SARC-CalF (SARC and calf circumference) scales were compared with five reference diagnostic criteria for sarcopenia.

Methods: This was a cross-sectional study. Patients diagnosed with diabetes were treated at the First Affiliated Hospital of Wenzhou Medical University. Appendicular skeletal muscle mass, muscle strength, and physical performance were assessed using dual-energy X-ray absorptiometry, handgrip strength, and gait speed assessment. Five diagnostic criteria for sarcopenia (Asian Working Group for Sarcopenia, International Working Group on Sarcopenia, Foundation for the National Institutes of Health, Sarcopenia Project, Society on Sarcopenia Cachexia and Wasting Disorders, and European Working Group on Sarcopenia in Older People criteria) were utilized. Sensitivity and specificity analyses were performed on the SARC-CalF and SARC-F scales. The diagnostic precision of both instruments was determined using the receiver-operating characteristic (ROC) curves and area under the ROC curves (AUC).

Results: This study included 689 subjects (459 men and 230 women) with a mean age of 58.1 ± 13.2 years. In accordance with the five reference diagnostic parameters, the prevalence of sarcopenia was between 4.5 and 19.2%. In addition, the range of sensitivity of SARC-F and SARC-CalF ranged from 61.4 to 67.4 and 82.6 to 91.8%, respectively. Concurrently, the specificity ranged from 63.1 to 67.3 and 51.5 to 61.2%, respectively. Overall, AUC values for SARC-CalF were higher than those for SARC-F, regardless of the diagnostic standard, sex, or age.

Conclusion: The results of this study suggest that SARC-CalF significantly enhances the sensitivity and overall diagnosis of SARC-F. SARC-CalF appears to be an optimal screening tool for sarcopenia in adults with T2DM.

Keywords: type 2 diabetes mellitus, sarcopenia, SARC-F, SARC-CalF, specificity, sensitivity, diagnostic criteria
INTRODUCTION

According to the definition, sarcopenia is the accelerated loss of skeletal muscle mass, muscle strength, and physical performance associated with old age or chronic disease. Additionally, it can result in negative effects, including falls, fractures, functional disability, enhanced hospital admission rates, reduced quality of life, and even death (1).

Diabetes mellitus (DM) is a metabolic disease that lasts for a lifetime. As individuals suffering from diabetes live longer, sarcopenia has recently been considered as one of the chronic complications of DM (1). Various studies have indicated that the prevalence of sarcopenia in people with type 2 DM (T2DM) is 1.56–3 times higher than in non-diabetics. In addition, sarcopenia is significantly related to glycemic control and the duration of diabetes (2–4). Therefore, early detection, early diagnosis, and treatment of sarcopenia in patients with diabetes are highly crucial. Current guidelines allow certain devices to evaluate body composition, such as computed tomography (CT), dual-energy X-ray absorption (DXA), and bioimpedance analysis (BIA). Nevertheless, since these devices are inaccessible in many clinical situations, a short and easy-to-use sarcopenia screening tool is needed (5, 6).

Several screening tools are available for screening sarcopenia. For instance, SARC-F, which was developed in 2013, is the most extensively applied questionnaire in several populations. SARC-F focuses on strength, assisting with walking, rising from a chair, climbing stairs, and falling (7). However, it has shown high specificity but low sensitivity, which may affect its potential as a screening tool for identifying individuals with sarcopenia (8–10). Recently, another tool for screening sarcopenia, known as SARC-CalF (SARC and calf circumference) (11), was reported by Sliva et al. This integrates SARC-F and calf circumference (CC), which greatly enhances the sensitivity and accuracy of SARC-F diagnosis. Yang et al. equally discovered similar results in Chinese elderly people (12, 13). Nevertheless, these results should be applied to diverse populations.

From what is known, people with diabetes have a higher tendency for developing sarcopenia; however, few studies have examined the diagnostic performance of SARC-F and SARC-CalF in predicting sarcopenia in adults with T2DM. Therefore, a cross-sectional study was performed to fill this gap.

MATERIALS AND METHODS

Study Design and Population

In this study, a diagnostic accuracy study was conducted. From June 2020 to June 2021, a total of 689 inpatients with T2DM according to the criteria of the American Diabetes Association of the Endocrinology Department were recruited at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. The exclusion criteria were as follows: (1) age ≤18 years; (2) type 1 DM (T1DM) and other types of DM; (3) malignant tumor; (4) autoimmune diseases; (5) taking medications that may affect body composition; (6) long-term bedridden patients; (7) severe disease of the heart, liver, or kidneys; and (8) inability to communicate with investigators.

All participants provided written informed consent. The study protocol utilized in this study was approved through the Clinical Research Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University.

Assessment of Sarcopenia With SARC-F and SARC-CalF

To evaluate sarcopenia risk, the SARC-F and SARC-CalF scales were implemented (Supplementary Table 1).

The SARC-F Scale

The SARC-F scale examines five domains: (1) strength; (2) HGS; (3) GS; (4) HGS; (5) GS; (6) long-term bedridden patients; (7) severe disease of the heart, liver, or kidneys; and (8) inability to communicate with investigators.

The SARC-CalF Scales

The SARC-CalF scale contains six objects; the first five objects have the same score as SARC-F, and the sixth object is CC. In accordance with the 2019 Asian Working Group for Sarcopenia (AWGS) criteria, CC thresholds were 34 and 33 cm for men and women, respectively. If the score is above the cut-off value, CC is scored as 0; if it is below the cut-off value, the score is 10. A score of ≥11 points indicates a positive screening for sarcopenia (5).

**TABLE 1** Five diagnostic criteria for sarcopenia and the cut-off applied.

| Diagnosis definition | Muscle mass | Muscle strength | Physical performance |
|----------------------|-------------|----------------|---------------------|
| EWGSOP1              | SMI ≤ 7.26 kg/m² for men | HGS < 30 kg for men | GS < 0.8 m/s for both gender |
|                      | SMI ≤ 5.50 kg/m² for women | HGS < 20 kg for women |                         |
| AWGS2019             | SMI < 7 kg/m² for men | HGS < 28 kg for men | GS < 1 m/s for both gender |
|                      | SMI < 5.4 kg/m² for women | HGS < 18 kg for men |                         |
| IWGS                 | SMI ≤ 7.2 kg/m² for men | HGS < 30 kg for men | GS < 0.8 m/s for both gender |
|                      | SMI ≤ 5.67 kg/m² for women | HGS < 20 kg for women |                         |
| SCWD                 | SMI ≤ 6.81 kg/m² for men | HGS < 28 kg for men | GS < 1 m/s for both gender |
|                      | SMI ≤ 5.18 kg/m² for women | HGS < 18 kg for men |                         |
| FNIH                 | ASM/BMI < 0.789 for men | HGS < 26 kg for men | GS < 1 m/s for both gender |
|                      | ASM/BMI < 0.512 for women | HGS < 16 kg for women |                         |

SMI, skeletal muscle mass index; ASM, appendicular skeletal muscle mass; BMI, body mass index; HGS, handgrip strength; GS, gait speed.
### Table 2: Characteristics of the study population.

| Variable                  | Overall (n = 689) | Men (n = 459) | Women (n = 230) | p-Value* |
|---------------------------|-------------------|---------------|-----------------|----------|
| Age (years)*              | 58.1 ± 13.2       | 56.4 ± 13.6   | 61.7 ± 11.7     | <0.001   |
| Diabetes duration (years)**| 10.0 (0.0, 15.0)  | 9.0 (2.0, 15.0)| 10.0 (5.0, 15.3)| 0.028    |
| HbA1c (%)†               | 9.6 ± 2.4         | 9.7 ± 2.4     | 9.3 ± 2.3       | 0.040    |
| FPG (mmol/L)†            | 8.9 ± 3.0         | 8.8 ± 2.8     | 9.1 ± 3.2       | 0.206    |
| 2hPG (mmol/L)†           | 19.8 ± 4.7        | 19.5 ± 4.6    | 20.4 ± 4.9      | 0.023    |
| HOMA-IR†                  | 2.7 (1.7, 4.6)    | 2.5 (1.5, 3.9)| 2.4 (1.9, 5.2)  | <0.001   |
| ALT (U/L)‡                | 21.0 (14.0, 32.0) | 23.0 (15.0, 35.0)| 17.0 (13.0, 25.0)| <0.001   |
| AST (U/L)‡                | 21.0 (17.0, 39.0) | 22.0 (17.0, 31.0)| 20.0 (17.0, 26.0)| 0.007    |
| eGFR‡                     | 95.2 ± 28.3       | 96.4 ± 30.6   | 92.8 ± 22.8     | 0.112    |
| BMI (kg/m²)‡             | 23.6 ± 3.4        | 23.7 ± 3.4    | 23.2 ± 3.3      | 0.076    |
| WC (cm)*                  | 90.1 ± 9.4        | 90.5 ± 9.4    | 89.3 ± 9.4      | 0.133    |
| CC (cm)*                  | 33.7 ± 3.6        | 34.3 ± 3.6    | 32.5 ± 3.2      | <0.001   |
| HGS (kg)*                 | 29.0 ± 10.5       | 33.6 ± 9.3    | 19.8 ± 5.8      | <0.001   |
| GS (m/24 h)‡              | 1.0 ± 0.2         | 1.0 ± 0.2     | 0.9 ± 0.2       | <0.001   |
| ASM (kg/m²)†              | 20.0 ± 4.4        | 22.1 ± 3.6    | 15.9 ± 2.6      | <0.001   |
| SMI (cm²/kg)‡             | 7.3 ± 1.2         | 7.7 ± 1.1     | 6.4 ± 0.9       | <0.001   |
| ASM/BMI‡†                 | 0.9 ± 0.2         | 0.9 ± 0.1     | 0.7 ± 0.1       | <0.001   |
| SARC-F®                   | 0.0 (0, 1)        | 0.0 (0, 1)    | 1.0 (1, 1)      | <0.001   |
| SARC-CalF©               | 3 (0, 10)         | 1 (0, 10)     | 10 (1, 11)      | <0.001   |

**ASM**, appendicular skeletal muscle mass; **SMI**, skeletal muscle mass index. The resistance; **AST**, aspartate aminotransferase; **ALT**, alanine aminotransferase; **GS**, gait speed; **ASM**, appendicular skeletal muscle mass; **SMI**, skeletal muscle mass index.

### Table 3: Sensitivity, specificity, PPV, NPV, LR, and AUC analyses for SARC-F and SARC-CalF validation against varying sarcopenia criteria.

| Table 3: Sensitivity, specificity, PPV, NPV, LR, and AUC analyses for SARC-F and SARC-CalF validation against varying sarcopenia criteria. | Overall (n = 689) | Men (n = 459) | Women (n = 230) | p-Value* |
|---------------------------------------------------------------|-------------------|---------------|-----------------|----------|
| **EWGSOPI classification†**                                  |                   |               |                 |          |
| Non-sarcopenia                                                | 658 (95.5%)       | 443 (96.5%)   | 215 (93.5%)     | <0.001   |
| Sarcopenia                                                   | 549 (79.7%)       | 386 (84.1%)   | 163 (70.9%)     |          |
| **AWGS2019 classification†**                                 |                   |               |                 |          |
| Non-sarcopenia                                                | 657 (80.8%)       | 362 (78.9%)   | 195 (84.8%)     |          |
| Sarcopenia                                                   | 557 (79.7%)       | 388 (86.4%)   | 163 (70.9%)     |          |
| **IWGS classification†**                                     |                   |               |                 |          |
| Non-sarcopenia                                                | 557 (80.8%)       | 362 (78.9%)   | 195 (84.8%)     |          |
| Sarcopenia                                                   | 557 (80.8%)       | 362 (78.9%)   | 195 (84.8%)     |          |
| **SCwD classification†**                                     |                   |               |                 |          |
| Non-sarcopenia                                                | 640 (92.9%)       | 421 (91.7%)   | 219 (95.2%)     |          |
| Sarcopenia                                                   | 49 (7.1%)         | 8 (17.9%)     | 33 (14.3%)      |          |
| **FNIH classification†**                                     |                   |               |                 |          |
| Non-sarcopenia                                                | 658 (95.5%)       | 434 (94.6%)   | 224 (97.4%)     |          |
| Sarcopenia                                                   | 556 (85.5%)       | 384 (84.6%)   | 172 (76.4%)     |          |

**Sensitivity, specificity, PPV, NPV, LR, and AUC** are calculated for the comparison between the SARC-F and SARC-CalF groups.

### Assessment of Muscle Mass, Muscle Strength, and Physical Performance

Muscle mass was assessed in each subject using DXA (Model: Prodigy Primo – 81013GA series; software 11.40.004, GE Healthcare United States, Shanghai Agent in Asia, Shanghai, China).
FIGURE 1 | The ROC curves of SARC-F and SARC-CalF were contrasted with various reference standards in the entire population studied: (A) sarcopenia according to the EWGSOP1 criteria; (B) sarcopenia according to AWGS2019 criteria; (C) sarcopenia according to IWGS criteria; (D) sarcopenia according to SCWD criteria; and (E) sarcopenia according to FNIH criteria.
China) by experienced radiologists. Before analysis, subjects were required to wear only a hospital gown and all-metal accessories. Scanning was taken while lying down. The software provides estimates of appendicular skeletal muscle mass (ASM), which is the sum of lean body mass in the upper and lower extremities (14). The ASM assessed and calculated the skeletal muscle mass index (SMI) and ASM/body mass index (BMI). The SMI was computed from the equation: SMI (kg/m²) = ASM (kg) / height² (m²).

The muscle strength was assessed on the basis of handgrip strength (HGS) using a portable electronic dynamometer with a precision of 0.1 kg (Brand: CAMRY, Model: TH-01, XIANGSHAN, Zhongshan, and Guangdong Province, China). Subjects who performed the HGS test were seated with their arms at their sides and with their elbows flexed at 90°. They squeezed the handle as hard as they could. Trained surveyors assessed the subject’s dominant hand three times, with an interval of 1 min between each measurement. All measured values were recorded, and the maximum value was taken as the muscle strength.

In this study, the gait speed (GS) test was measured as the physical performance. The subjects were instructed to walk a distance of 6 m in their normal gait. If necessary, canes and walkers were adopted. The GS measurement was performed twice with an accuracy of 0.1 m, and the mean value was recorded.

### Clinical Data

General clinical data, such as demographic information, duration of illness, medical history, and medication status, were collected.

All anthropometric measurements were performed in the morning without eating before the assessments. Trained nurses measured weight (kg) and height (m) at 0.1 kg and 0.1 cm, respectively. BMI (kg/m²) was computed as the body weight divided by the square of the height. The CC was assessed with an accuracy of 0.1 m, and the mean value was recorded.

### Assessment of Sarcopenia Using Different Diagnostic Criteria

The five diagnostic classifications are utilized for screening sarcopenia: (1) the European Working Group on Sarcopenia in Older People (EWGSOP) (17); (2) the AWGS (5); (3) the International Working Group on Sarcopenia (IWGS) (18); (4) the Society on Sarcopenia Cachexia and Wasting Disorders (SCWD) (19); and (5) the Foundation for the National Institutes of Health (FNHI) Sarcopenia Project (20).

### Table 4 | Sensitivity, specificity, PPV, NPV, +LR, and −LR analyses and ROC curves for SARC-F and SARC-CalF validation against different sarcopenia criteria in men.

| Classification | Sensitivity % | Specificity % | PPV % | NPV % | +LR | −LR | AUC | p-Value |
|----------------|--------------|--------------|-------|-------|-----|-----|-----|---------|
| EWGSOP1        |              |              |       |       |     |     |     |         |
| SARC-F         | 55.7 (45.2–65.8) | 74.9 (70.1–79.2) | 37.2 (31.6–43.3) | 66.3 (83.3–88.8) | 2.2 (1.7–2.8) | 0.6 (0.5–0.7) | 0.67 (0.62–0.71) | <0.001 |
| SARC-CalF      | 83.5 (74.6–90.3) | 64.6 (59.5–69.6) | 38.8 (34.9–42.7) | 93.6 (90.3–95.8) | 2.4 (2.0–2.8) | 0.3 (0.2–0.4) | 0.80 (0.76–0.84) |         |
| AWGS2019       |              |              |       |       |     |     |     |         |
| SARC-F         | 57.3 (45.9–68.2) | 74.0 (69.3–78.4) | 32.4 (27.1–38.2) | 88.9 (86.0–91.2) | 2.2 (1.7–2.8) | 0.6 (0.4–0.7) | 0.67 (0.63–0.71) | <0.001 |
| SARC-CalF      | 86.6 (77.3–93.1) | 66.8 (61.8–71.6) | 36.2 (32.5–40.2) | 95.8 (92.9–97.6) | 2.6 (2.2–3.1) | 0.2 (0.1–0.3) | 0.83 (0.79–0.86) |         |
| IWGS           |              |              |       |       |     |     |     |         |
| SARC-F         | 62.5 (48.5–75.1) | 72.7 (68.1–77.0) | 24.1 (19.7–29.2) | 93.3 (90.8–95.2) | 2.3 (1.8–3.0) | 0.5 (0.4–0.7) | 0.68 (0.64–0.72) | <0.001 |
| SARC-CalF      | 91.1 (80.4–97.0) | 57.3 (52.3–62.2) | 22.9 (20.5–25.4) | 97.9 (95.2–99.1) | 2.1 (1.9–2.5) | 0.2 (0.1–0.4) | 0.80 (0.77–0.84) |         |
| SCWD           |              |              |       |       |     |     |     |         |
| SARC-F         | 63.2 (48.0–78.2) | 71.3 (66.7–75.5) | 16.6 (13.0–20.9) | 95.5 (93.4–97.0) | 2.2 (1.7–2.9) | 0.5 (0.3–0.8) | 0.67 (0.62–0.71) | <0.001 |
| SARC-CalF      | 86.8 (71.9–95.6) | 61.3 (56.4–66.0) | 16.8 (14.6–19.4) | 98.1 (95.8–99.2) | 2.2 (1.9–2.7) | 0.2 (0.1–0.5) | 0.80 (0.76–0.84) |         |
| FNHI           |              |              |       |       |     |     |     |         |
| SARC-F         | 64.0 (42.5–82.0) | 70.3 (65.7–74.5) | 11.0 (8.2–14.7) | 97.1 (95.2–98.3) | 2.2 (1.6–3.0) | 0.5 (0.3–0.9) | 0.68 (0.64–0.72) | 0.076 |
| SARC-CalF      | 92.0 (74.0–99.0) | 57.1 (52.3–61.9) | 11.0 (9.5–12.7) | 99.2 (97.0–99.8) | 2.2 (1.8–2.5) | 0.2 (0.1–0.5) | 0.77 (0.73–0.81) |         |

PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; −LR, negative likelihood ratio; AUC, area under the ROC curves. Values within parentheses represent the 95% confidential intervals.

a The p-value represents the difference between the SARC-F and SARC-CalF groups.
FIGURE 2 | The ROC curves of SARC-F and SARC-CalF compared with various reference standards in men: (A) sarcopenia according to the EWGSOP1 criteria; (B) sarcopenia according to AWGS2019 criteria; (C) sarcopenia according to IWGS criteria; (D) sarcopenia according to SCWD criteria; and (E) sarcopenia according to FNIH criteria.
Sarcopenia was defined according to the EWGSOP1 and AWGS2019 criteria as low muscle mass, in addition to low muscle strength or low physical performance. According to the IWGS and SCWD criteria, sarcopenia is defined as low muscle mass and poor physical performance. According to the FNHI recommendation, sarcopenia is defined as a low muscle mass associated with low muscle strength. Various diagnostic criteria recommended different cut-off values and were inconsistent for both sexes. The comprehensive criteria used in this study are listed in Table 1.

**Statistical Analysis**

SPSS software (version 23.0; SPSS Statistics, IBM, Armonk, NY, United States) and MedCalc statistical software (version 19.0; MedCalc software bvba, Ostend, Belgium) were used for statistical analysis. A two-tailed p-value of < 0.05 was considered to indicate significant differences.

The clinical properties of the substances between men and women were compared. Continuous variables with a normal distribution were presented as mean ± SD. For continuous variables with skewed distributions, data were presented as the median (interquartile range). Student’s t-test and Mann–Whitney U-test were used to compare continuous variables. For categorical variables, data were presented as numbers (percentage). The X² test was used to compare the categorical variables.

The EWGSOP1, AWGS2019, IWGS, SCWD, and FNHI were used as reference standards. The diagnostic value was calculated, for instance, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), and negative likelihood ratio (−LR) for SARC-F and SARC-CalF to screen for sarcopenia. The receiver-operating characteristic (ROC) curve was used to compare the overall diagnostic precision and calculate the area under the ROC curves (AUC) at a 95% confidence interval (CI). Overall, AUCs < 0.5, 0.5–0.7, 0.7–0.9, and > 0.9 demonstrate that a tool has no, low, moderate, and high diagnostic values (21). The AUC values for each ROC curve were compared using the DeLong method (22). The data were also stratified by age and sex to investigate the capacity and application of the two screening tools.

### RESULTS

#### Subjects’ Description and Characteristics

In total, 689 T2DM inpatients from our clinic were available for assessment. Regarding the population sample, there are about 459 men and 230 women with a mean age of 56.4 ± 13.6 years for men and 61.7 ± 11.7 years for women. The properties of the substances according to sex are summarized in Table 2. In accordance to the table, women had a higher mean age than men (p < 0.001), duration of diabetes (p = 0.028), 2hPG (p = 0.023), HOMA-IR (p < 0.001), SARC-F scores (p < 0.001), and SARC-CalF scores (p < 0.001). In contrast, men had considerably higher levels of ALT (p < 0.001), AST (p = 0.007), CC (p < 0.001), HGS (p < 0.001), GS (p < 0.001), SMI (p < 0.001), and ASM/IMC (p < 0.001). Additionally, FPG, eGFR, BMI, and WC were not significantly different between the two groups.

#### Prevalence of Sarcopenia

Table 2 presents the incidence of sarcopenia according to the two screening instruments and the five diagnostic criteria. In the entire study population, the median scores for SARC-F and SARC-CalF were 0 and 3, respectively. Based on SARC-F and SARC-CalF, the prevalence of sarcopenia in our study population

| Table 5 | Analysis of the curves of sensitivity, specificity, PPV, VPN, +LR, and −LR and ROC for the validation of SARC-F and SARC-CalF against various criteria of sarcopenia in women. |
|-------------|------------------|----------------|---------|---------|--------|--------|-------|
| **EWGSOP1 classification** | **Sensitivity %** | **Specificity %** | **PPV %** | **NPV %** | **+LR** | **−LR** | **AUC** |
| SARC-F | 51.4 (34.0–68.6) | 83.1 (77.1–88.1) | 35.3 (25.9–46.0) | 90.5 (87.1–93.1) | 3.0 (1.9–4.8) | 0.6 (0.4–0.8) | 0.72 (0.65–0.77) | 0.025 |
| SARC-CalF | 68.6 (50.7–83.1) | 78.0 (71.5–83.6) | 35.8 (28.3–44.1) | 93.3 (89.4–96.8) | 3.1 (2.2–4.4) | 0.4 (0.2–0.7) | 0.80 (0.74–0.85) |
| **AWGS2019 classification** | **Sensitivity %** | **Specificity %** | **PPV %** | **NPV %** | **+LR** | **−LR** | **AUC** |
| SARC-F | 48.5 (30.8–66.5) | 82.2 (76.2–87.3) | 31.4 (22.4–42.1) | 90.5 (87.2–93.0) | 2.7 (1.7–4.3) | 0.6 (0.4–0.9) | 0.70 (0.63–0.75) | 0.005 |
| SARC-CalF | 69.7 (51.3–84.4) | 77.7 (71.2–83.3) | 34.3 (27.0–42.4) | 93.9 (90.1–96.3) | 3.1 (2.2–4.4) | 0.4 (0.2–0.7) | 0.80 (0.74–0.85) |
| **IWGS classification** | **Sensitivity %** | **Specificity %** | **PPV %** | **NPV %** | **+LR** | **−LR** | **AUC** |
| SARC-F | 38.5 (20.2–59.4) | 79.9 (73.7–85.2) | 19.6 (12.3–29.9) | 91.1 (88.2–93.3) | 1.9 (1.1–3.3) | 0.8 (0.6–1.1) | 0.61 (0.54–0.67) | 0.006 |
| SARC-CalF | 88.5 (69.8–97.6) | 48.0 (41.0–55.1) | 17.8 (15.2–20.8) | 97.0 (91.8–99.0) | 1.7 (1.4–2.1) | 0.2 (0.1–0.7) | 0.73 (0.67–0.79) |
| **SCWD classification** | **Sensitivity %** | **Specificity %** | **PPV %** | **NPV %** | **+LR** | **−LR** | **AUC** |
| SARC-F | 54.8 (23.4–83.3) | 79.5 (73.5–84.6) | 11.8 (6.8–19.5) | 97.2 (94.8–98.5) | 2.7 (1.5–4.8) | 0.6 (0.3–1.1) | 0.70 (0.64–0.76) | 0.248 |
| SARC-CalF | 72.7 (39.9–94.0) | 73.1 (66.7–78.8) | 11.9 (8.2–17.1) | 98.2 (95.3–99.3) | 2.7 (1.8–4.1) | 0.4 (0.1–1.0) | 0.78 (0.72–0.83) |
| **FNHI classification** | **Sensitivity %** | **Specificity %** | **PPV %** | **NPV %** | **+LR** | **−LR** | **AUC** |
| SARC-F | 50.0 (11.8–88.2) | 78.6 (72.6–83.8) | 5.9 (2.6–12.6) | 98.3 (96.3–99.2) | 2.3 (1.0–5.4) | 0.6 (0.3–1.4) | 0.62 (0.56–0.69) | 0.227 |
| SARC-CalF | 66.7 (22.3–95.7) | 71.9 (65.5–77.7) | 6.0 (3.4–10.4) | 98.8 (96.3–99.6) | 2.4 (1.3–4.3) | 0.5 (0.1–1.4) | 0.70 (0.64–0.76) |

PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; −LR, negative likelihood ratio; AUC, area under the ROC curves. Values within parentheses represent the 95% confidential intervals.

*The p-value represents the difference between the SARC-F and SARC-CalF groups.*
FIGURE 3 | The ROC curves of SARC-F and SARC-CalF compared with various reference standards in women: (A) sarcopenia according to the EWGSOP1 criteria; (B) sarcopenia according to AWGS2019 criteria; (C) sarcopenia according to IWGS criteria; (D) sarcopenia according to SCWD criteria; and (E) sarcopenia according to FNIH criteria.
was 4.5 and 20.3%, respectively. According to the recommended cut-off values for various diagnostic criteria, the prevalence of sarcopenia was 19.2, 16.7, 11.9, 7.1, and 4.5%. The prevalence of sarcopenia varied between 5.4 and 21.1% in men and 2.6 and 15.2% in women. Irrespective of the reference benchmarks applied, sarcopenia was more common in men than in women; however, the differences were not significant.

**Comparison of SARC-F and SARC-CalF in the Whole Study Population**

Table 3 presents the results of sensitivity/specificity analyses, as well as the AUC of SARC-F and SARC-CalF in the course of applying various diagnostic criteria as the reference benchmark. The sensitivity of the two tools varied in the following ranges: SARC-F, 61.4–67.4%; and SARC-CalF, 82.6–91.8%. The values of the specificity ranges were as follows: SARC-F, 63.1–67.3%; and SARC-CalF, 51.5–61.2%. The PPV outcomes ranged from 7.6% (for SARC-F against FNIH) to 33.5% (for SARC-CalF against EWGSOP1), while a deviation is recorded in NPV as it varies from 88.0% (for SARC-F against EWGSOP1) to 99.1% (for SARC-CalF against FNIH). Irrespective of the type of diagnostic criteria utilized as the reference standard, compared to the SARC-F, the SARC-CalF had more suitable sensitivity and lower specificity.

As shown in Figure 1, the ROC curves of the two screening tools against various standards in the entire study population are plotted. The ranges of AUCs of SARC-F and SARC-CalF are 0.65–0.67 and 0.74–0.81, respectively. Regarding the AUCs, unless the FNIH criteria were implemented, the SARC-CalF are 0.65–0.67 and 0.74–0.81, respectively. Regarding the application of the EWGSOP1 criteria, the respective AUC values for SARC-F and SARC-CalF were 0.67 and 0.80. Therefore, the difference was significant \( p < 0.001 \). In this study, the corresponding outcomes were obtained using AWGS2019, IWGS, and SCWD. Assuming that the FNIH criteria were applied, there was no significant difference \( p = 0.076 \).

**Comparison of SARC-F and SARC-CalF in Each Sex**

Table 4 presents the results of sensitivity/specificity analyses and AUCs of SARC-F and SARC-CalF in humans using various diagnostic criteria as reference standards. In men, SARC-CalF displayed more suitable sensitivity as a reference standard, regardless of diagnostic criteria; however, in contrast with SARC-F, it displays a lower specificity. For instance, using EWGSOP1 as a reference standard, the sensitivities of SARC-F and SARC-CalF were 55.7 and 83.5%, and the specificities were 74.9 and 64.6%, respectively. In Figure 2, the ROC curves for SARC-F and SARC-CalF against various reference standards in men are depicted. Through the application of the EWGSOP1 criteria, the respective AUC values for SARC-F and SARC-CalF were 0.67 and 0.80. Therefore, the difference was significant \( p < 0.001 \). In this study, the corresponding outcomes were obtained using AWGS2019, IWGS, and SCWD. Assuming that the FNIH criteria were applied, there was no significant difference \( p = 0.076 \).

**Table 5** presents the results of sensitivity/specificity analyses, as well as the AUCs of SARC-F and SARC-CalF in women with diverse diagnostic criteria serving as a reference benchmark. Regardless of the adopted reference standard utilized for women, SARC-CalF equally demonstrated more suitable sensitivity and identical specificity in contrast to SARC-F. For instance, when using EWGSOP1 as the reference standard, the sensitivities of SARC-F and SARC-CalF were 51.4 and 68.6%, and the specificities were 83.1 and 78.0%, respectively. The ROC curves for SARC-F and SARC-CalF against various reference standards

---

**Table 6** presents the results of sensitivity/specificity analyses, as well as the AUC of SARC-F and SARC-CalF validation against various sarcopenia criteria in the older group.

| Diagnostic Criteria | Sensitivity % | Specificity % | PPV % | NPV % | +LR | −LR | AUC | p-Value
|---------------------|--------------|--------------|-------|-------|-----|-----|-----|---------|
| EWGSOP1 classification |
| SARC-F | 41.1 (30.8–52.0) | 80.7 (75.0–85.6) | 45.1 (36.4–54.1) | 78.0 (74.7–81.0) | 2.1 (1.5–3.1) | 0.7 (0.6–0.9) | 0.63 (0.57–0.68) | <0.001 |
| SARC-CalF | 84.4 (75.3–91.2) | 54.9 (48.3–61.4) | 42.0 (38.0–46.1) | 90.1 (84.8–93.8) | 1.9 (1.6–2.2) | 0.3 (0.2–0.5) | 0.75 (0.70–0.80) | <0.001 |
| AWGS2019 classification |
| SARC-F | 42.5 (31.0–54.6) | 79.6 (74.1–84.4) | 37.8 (29.7–46.6) | 82.6 (79.4–85.4) | 2.1 (1.4–3.0) | 0.7 (0.6–0.9) | 0.64 (0.58–0.69) | <0.001 |
| SARC-CalF | 90.4 (81.2–96.1) | 54.0 (47.6–60.3) | 36.5 (33.0–40.1) | 95.1 (90.4–97.5) | 2.0 (1.7–2.3) | 0.2 (0.1–0.4) | 0.78 (0.74–0.83) | <0.001 |
| IWGS classification |
| SARC-F | 66.0 (51.7–78.5) | 51.9 (45.7–57.9) | 21.2 (17.6–25.3) | 88.6 (84.0–92.0) | 1.4 (1.1–1.7) | 0.7 (0.4–1.0) | 0.60 (0.54–0.65) | <0.001 |
| SARC-CalF | 88.7 (77.0–95.7) | 50.4 (44.2–56.5) | 26.0 (23.1–29.0) | 95.8 (91.4–98.0) | 1.8 (1.5–2.1) | 0.2 (0.1–0.5) | 0.73 (0.68–0.78) | <0.001 |
| SCWD classification |
| SARC-F | 69.0 (49.2–84.7) | 50.7 (44.8–56.5) | 12.1 (9.5–15.3) | 94.3 (90.5–96.6) | 1.4 (1.1–1.8) | 0.6 (0.4–1.1) | 0.59 (0.53–0.64) | <0.001 |
| SARC-CalF | 93.1 (77.2–99.2) | 47.6 (41.8–53.5) | 14.9 (13.1–16.9) | 98.8 (94.8–99.6) | 1.8 (1.5–2.1) | 0.2 (0.1–0.6) | 0.73 (0.68–0.78) | <0.001 |
| FNIH classification |
| SARC-F | 68.0 (46.5–85.1) | 50.3 (44.5–56.2) | 10.3 (7.9–13.3) | 94.9 (91.3–97.1) | 1.4 (1.0–1.8) | 0.6 (0.4–1.1) | 0.60 (0.54–0.65) | 0.195 |
| SARC-CalF | 92.0 (74.0–99.0) | 42.0 (36.3–47.8) | 11.7 (10.3–13.4) | 98.4 (94.3–99.6) | 1.6 (1.4–1.8) | 0.2 (0.1–0.7) | 0.67 (0.61–0.72) | <0.001 |

PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; −LR, negative likelihood ratio; AUC, area under the ROC curves. Values within parentheses represent the 95% confidential intervals. aThe p-value represents the difference between the SARC-F and SARC-CalF groups.
FIGURE 4 | The ROC curves of SARC-F and SARC-CalF compared with various reference norms in the older group: (A) sarcopenia according to the EWGSOP1 criteria; (B) sarcopenia according to AWGS2019 criteria; (C) sarcopenia according to IWGS criteria; (D) sarcopenia according to SCWD criteria; and (E) sarcopenia according to FNIH criteria.
in women are shown in Figure 3. Using the EWGSOP1 criteria, the AUCs for SARC-F and SARC-CalF were 0.72 and 0.80, respectively. There was a significant difference between the groups (p = 0.025). With the assistance of AWGS2019 and IWGS, similar results were obtained. The AUC of SARC-CalF is moderate when applied to different sensitivities to various reference benchmarks when applied for different sexes.

**Comparison of SARC-F and SARC-CalF in Each Age Group**

Table 6 presents the screening potential of SARC-F alongside SARC-CalF in subjects aged ≥60 years during the application of various diagnostic criteria as reference standards. Sensitivity/specificity analyses showed related results in the older group, in contrast to the entire study population. The sensitivity of the two instruments varied in the following areas: SARC-F, 41.1–69.0%; and SARC-CalF, 84.4–93.1%. The ranges of specificity were as follows: SARC-F, 50.3–80.7%; and SARC-CalF, 42.0–54.9%. As shown in Figure 4, during the process of applying the EWGSOP1, AWGS2019, IWGS, and SCWD, the variation in AUC between SARC-F and SARC-CalF was generally significant. Table 7 presents the screening potentials of SARC-F and SARC-CalF in subjects aged <60 years with varying diagnostic criteria as a reference standard. In the younger group, the sensitivity of the two instruments varied in the following areas: SARC-F, 33.3–65.0%; and SARC-CalF, 83.3–90.0%. The ranges of specificity were as follows: SARC-F, 75.4–92.2%; and SARC-CalF, 59.3–62.4%. As shown in Figure 5, there is a significant variation in AUC between SARC-F and SARC-CalF when the EWGSOP1, AWGS2019, and IWGS criteria were applied. In the category of older subjects, the AUC of the two instruments was from 0.59 to 0.78, while it was from 0.64 to 0.82 in younger subjects. Therefore, a comparison of both groups demonstrated that the AUC of the two screening tools was higher in the younger subjects than in the older subjects. Furthermore, it was observed that the increase in age is directly proportional to the increase in sensitivity to SARC-CalF. In contrast, a contradictory trend was demonstrated in the specificity of SARC-CalF.

**DISCUSSION**

This study showed that SARC-CalF was significantly more suitable than SARC-F in sarcopenia screening for patients with T2DM in terms of sensitivity and general diagnostic accuracy using varying criteria as a gold benchmark. Since sarcopenia is associated with serious consequences on the health of older subjects, early recommendation of preventive strategies is highly necessary. Thus, from a clinical perspective, it is essential to provide an early diagnosis using simple and effective sarcopenia screening tools, preferably, a screening tool exhibiting high sensitivity while simultaneously maintaining high specificity (23).

Based on the general consensus about sarcopenia, for diagnosis confirmation, it has been demonstrated that low muscle mass and function are essential. SARC-F is the first screening tool for sarcopenia and has been widely applied in the field of sarcopenia. Thus far, the validation of the research has been implemented in China (8, 12, 24), America (25), Japan (26), Turkey (10), and Brazil (27, 28), to mention a few. Nevertheless, previous studies have revealed that it has high specificity and low sensitivity. A novel study conducted by Parra-Rodríguez et al. revealed that in 487 men and women, the sensitivity to SARC-F was 35.6% with a specificity of 82.2% (9). The outcome of this study corresponds to the results of Woo et al., which revealed that the sensitivity and specificity of SARC-F were 9.9 and 94.4%, respectively.

**TABLE 7 | Sensitivity, specificity, PPV, NPV, +LR, and −LR assessments and ROC curves for SARC-F and SARC-CalF validation against various criteria of sarcopenia in the group comprising of the younger group.**

| EWGSOP1 classification | Sensitivity % | Specificity % | PPV % | NPV % | +LR | −LR | AUC | p-Value<sup>a</sup> |
|------------------------|--------------|---------------|-------|-------|-----|-----|-----|-----------------|
| SARC-F                 | 57.1 (41.0–72.3) | 77.2 (72.2–81.6) | 24.5 (18.9–31.1) | 93.3 (90.7–95.2) | 2.5 (1.8–3.5) | 0.6 (0.4–0.8) | 0.69 (0.64–0.73) | 0.005 |
| SARC-CalF              | 83.3 (68.6–93.0) | 61.7 (56.2–67.0) | 22.0 (18.9–25.5) | 96.6 (93.5–98.3) | 2.2 (1.8–2.6) | 0.3 (0.1–0.5) | 0.80 (0.76–0.84) |       |
| AWGS2019 classification| SARC-F       | 54.8 (38.7–70.2) | 76.9 (71.9–81.3) | 23.5 (17.9–30.1) | 92.9 (90.3–94.8) | 2.4 (1.7–3.3) | 0.6 (0.4–0.8) | 0.67 (0.62–0.72) | <0.001 |
|                       | SARC-CalF    | 88.1 (74.4–96.0) | 62.4 (56.8–67.6) | 23.3 (20.2–26.6) | 97.6 (94.6–98.9) | 2.3 (2.0–2.8) | 0.2 (0.1–0.4) | 0.82 (0.77–0.85) |       |
| IWGS classification    | SARC-F       | 58.6 (38.9–76.5) | 76.0 (71.0–80.4) | 17.3 (12.8–23.1) | 95.5 (93.2–97.1) | 2.4 (1.7–3.5) | 0.5 (0.4–0.8) | 0.68 (0.63–0.73) | 0.017 |
|                       | SARC-CalF    | 89.7 (72.6–97.8) | 60.5 (55.1–65.8) | 16.4 (14.0–19.0) | 98.6 (96.9–99.5) | 2.3 (1.9–2.7) | 0.2 (0.1–0.5) | 0.79 (0.75–0.83) |       |
| SCWD classification    | SARC-F       | 65.0 (40.8–84.6) | 75.4 (70.5–79.9) | 13.3 (9.5–18.1)  | 97.4 (96.3–98.5) | 2.7 (1.8–3.8) | 0.5 (0.3–0.8) | 0.72 (0.67–0.76) | 0.090 |
|                       | SARC-CalF    | 90.0 (68.3–98.8) | 59.3 (53.9–64.5) | 11.3 (9.5–13.4)  | 99.0 (96.5–99.7) | 2.2 (1.8–2.7) | 0.2 (0.1–0.6) | 0.80 (0.76–0.84) |       |
| FNIH classification    | SARC-F       | 33.3 (4.3–77.7)  | 92.2 (89.0–94.8) | 6.7 (2.1–19.0)   | 98.8 (97.9–99.3) | 4.3 (1.3–14.0) | 0.7 (0.4–1.3) | 0.64 (0.59–0.69) | 0.143 |
|                       | SARC-CalF    | 83.3 (35.9–99.6) | 61.4 (56.1–66.4) | 3.5 (2.4–5.0)    | 99.5 (97.4–99.9) | 2.2 (1.5–3.2) | 0.3 (0.1–1.6) | 0.77 (0.72–0.81) |       |

PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; −LR, negative likelihood ratio; AUC, area under the ROC curves. Values within parentheses represent the 95% confidence intervals.

<sup>a</sup>The p-value represents the difference between the SARC-F and SARC-CalF groups.
FIGURE 5 | The ROC curves of SARC-F and SARC-CalF compared with various reference standards in the category of younger subjects: (A) sarcopenia according to the EWGSOP1 criteria; (B) sarcopenia according to AWGS2019 criteria; (C) sarcopenia according to IWGS criteria; (D) sarcopenia according to SCWD criteria; and (E) sarcopenia according to FNIH criteria.
respectively (8). Thus, due to the low sensitivity of SARC-F, it has subsequently brought about limitations to its clinical application.

From the findings of Kawakami et al., a positive correlation was found between CC and muscle mass (29). Furthermore, the SARC-CalF, integrating CC and SARC-F, was developed by Barbosa-Silva. This research, which involved 179 older people in communities in Brazil, found that the sensitivity and specificity of SARC-CalF were 66.7 and 82.9%, respectively (11). Following the application of the same standard, it was reported by Yang et al. that SARC-CalF with sensitivity and specificity in Chinese nursing home occupants was 58.9 and 84.5%, respectively (13). Therefore, it was proposed by the above researchers that SARC-CalF should be utilized as a modified version for enhancing the sensitivity of SARC-F (11). In this study, the sensitivity and specificity displayed by SARC-CalF were 82.6 and 61.2%, respectively, by applying the EWGSOP1 criteria. In contrast to past research, this study showed relatively lower specificity, albeit a higher sensitivity, possibly as a result of the varying clinical features (race, sex, and age) of the subjects. In addition, all subjects in the study have diabetes. Applying various diagnostic criteria, the AUC of SARC-F ranged from 0.65 to 0.67, and the AUC of SARC-CalF ranged from 0.74 to 0.81. Thus, SARC-F displayed low diagnostic precision, and SARC-CalF demonstrated moderate diagnostic accuracy. In general, with regard to the screening for sarcopenia in adults with T2DM, SARC-CalF is more effective than SARC-F.

This study demonstrated that sex and age could affect the screening potential of the two screening tools. Overall, men tend to overestimate their physical abilities (30), while women could underestimate their physical abilities because of their diverse perceptions. The results of this study showed that SARC-F and SARC-CalF have significantly higher values in women than in men. Regarding sex, SARC-CalF in men showed higher sensitivity and AUC compared with women. This result in contrast to the conclusion of Mo et al. (31). Moreover, age was one of the criteria. In general, the specificity and AUC of SARC-CalF decreased with age. In contrast, the trend displayed by the sensitivity of SARC-CalF showed the opposite trend. This result corroborate the study by Mo et al. (31).

Calf circumference tends to be profoundly impacted by obesity and edema, which may mask sarcopenia (13, 32). Nevertheless, various optimal cut-off points exist for CC in various ethnic groups. Kawakami et al. utilized 34 and 33 cm as cut-off points for CC in Japanese men and women, respectively, in estimating low muscle mass (29). In a Turkish study, 33 cm was proposed as the threshold point for CC in men and women (33). In a recent study conducted by Hwang et al. in Taiwan, sections were recorded at 33 and 32 cm to predict sarcopenia in men and women, respectively. In our study, the median CC in men and women was 34 and 33 cm, respectively. Thus, the cut-off values of the screening recommended by the AWGS2019 consensus are appropriate for subjects utilized in this study.

Recent studies have reported that the CC per se was better than the SARC-F and SARC-CalF (31, 34, 35). Our data demonstrated that although both the SARC-CalF and CC outperformed the SARC-F, demonstrating moderate diagnostic accuracy; the CC per se was not significantly better than the SARC-CalF. In contrast, the SARC-CalF was slightly more sensitive than the CC. This finding should be addressed in future studies with larger sample sizes. Overall, the conclusions remain unchanged. These data are shown in Supplementary Table 2. Moreover, a novel tool, known as the mini sarcopenia risk assessment (MSRA) questionnaire, was developed by Rossi et al., with sensitivity and specificity of 80.4 and 60.4%, respectively. The MSRA includes a comprehensive evaluation and nutritional assessment (36). This scale was validated in the study by Ming-Yang et al. in various populations and subsequently surmised that MSRA-5 could act as a dependable and valid tool for screening sarcopenia (13, 37). Through the application of age, as well as BMI, Kurita et al. enhanced SARC-F and named this modified version SARC-F + EBM (38). In 2019, research conducted on 959 hospitalized Japanese patients showed that SARC-F + EBM had higher sensitivity than SARC-F, with a sensitivity of 77.8% and a specificity of 69.6% (38). Thus, the validation and comparison of these new screening tools in adults with T2DM should be evaluated in subsequent studies.

Certain drawbacks of this study need to be addressed. First, this study focused initially only on hospitalized patients with T2DM. Thus, this study outcome may not be appropriate for older people residing in the community. Second, cognitive functions were not assessed because our subjects were relatively young. Notwithstanding, SARC-F was developed based on the elderly population. Third, the prognostic value of SARC-F and SARC-CalF for adverse outcomes should be considered in future prospective studies as a cross-sectional study.

**CONCLUSION**

In summary, early detection and intervention of sarcopenia are crucial. Regardless of the reference standard, sex, and age, SARC-CalF displayed more suitable sensitivity and diagnostic performance than SARC-F. Thus, SARC-CalF appears to be a more appropriate screening tool for sarcopenia in adults with T2DM. Subsequent research is needed to validate the utility of SARC-CalF in various populations and frameworks.

**STANDARD BIOSECURITY AND INSTITUTIONAL SAFETY PROCEDURES**

All institutional security procedures were followed and biosecurity metrics were implemented. The hospital laboratory utilized for this research has a biosafety level 2 (BSL-2) standard, implying that all standards and protocols have been implemented in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI).

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

HZ conceived and designed this manuscript. JJ, ZZ, and YC conducted the data collection and participants’ recruiting exercises. HZ and ZX conducted the data analysis and interpretation. ZX and PZ prepared the manuscript. All authors in this study contributed to the article and subsequently approved the submitted version.

REFERENCES

1. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options – a mini-review. Gerontology. (2014) 60:294–305. doi: 10.1159/000356760
2. Wang T, Feng X, Zhou J, Gong H, Xia S, Wei Q, et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep. (2016) 6:38937. doi: 10.1038/srep38937
3. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. (2007) 30:1507–12. doi: 10.2337/dc07-0253
4. Koo BK, Roh E, Yang YS, Moon MK. Difference between old and young adults in contribution of beta-cell function and sarcopenia in developing diabetes mellitus. J Diabetes Investig. (2016) 7:233–40. doi: 10.1111/jdi.12392
5. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Jijima K, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. (2020) 21:300–7.e2. doi: 10.1016/j.jamda.2019.12.012
6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Aging. (2019) 48:16–31. doi: 10.1093/ageing/afy169
7. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. (2013) 14:531–2. doi: 10.1016/j.jamda.2013.05.018
8. Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. (2014) 15:630–4. doi: 10.1016/j.jamda.2014.04.021
9. Parra-Rodriguez L, Silef C, Garcia-Gonzalez AI, Malmstrom TK, Cruz-Arenas E, Rosas-Carrasco O. Cross-cultural adaptation and validation of the Spanish-language version of the SARC-F to assess sarcopenia in Mexican community-dwelling older adults. J Am Med Dir Assoc. (2016) 17:1142–6. doi: 10.1016/j.jamda.2016.09.008
10. Bahat G, Yilmaz O, Kilic C, Oren MM, Karan MA. Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging. (2018) 22:898–903. doi: 10.1007/s12603-018-1067-8
11. Barbosa-Silva TG, Menezes AM, Bielmeier RM, Malmstrom TK, Gonzalez MC. Grupo de estudos em composicao corporal e n. enhancing SARC-F: improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc. (2016) 17:1136–41. doi: 10.1016/j.jamda.2016.08.004
12. Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al. Screening sarcopenia in community-dwelling older adults: SARC-F vs SARC-F combined with calf circumference (SARC-CalF). J Am Med Dir Assoc. (2018) 19:297.e1–8. doi: 10.1016/j.jamda.2017.12.016
13. Yang M, Lu J, Jiang J, Zeng Y, Tang H. Comparison of four sarcopenia screening tools in nursing home residents. Aging Clin Exp Res. (2019) 31:1481–9. doi: 10.1007/s40520-018-1083-x
14. Heymsfield SB, Stanley A, Pietrobelli A, Heo M. Simple skeletal muscle mass estimation formulas: what we can learn from them. Front Endocrinol (Lisbon). (2020) 11:31. doi: 10.3389/fendo.2020.00031
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. (1985) 28:412–9. doi: 10.1007/BF00280883
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
17. Cruz-Jentoft AJ, Baeyens JP, Bauer M, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. (2010) 39:412–23. doi: 10.1093/ageing/afq034
18. Fielding RA, Vellas B, Evans WJ, Baracos V, Bauer J, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition, prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. (2011) 12:249–56. doi: 10.1016/j.jamda.2011.01.003
19. Morley JE, Abbatecola AM, Argles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. (2011) 12:403–9. doi: 10.1016/j.jamda.2011.04.014
20. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. (2014) 69:547–58. doi: 10.1093/gerona/glut10
21. Linden A. Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract. (2006) 12:132–9. doi: 10.1111/j.1365-2753.2005.00598.x
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. (1988) 44:857–65.
23. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. (2002) 359:881–4. doi: 10.1016/S0140-6736(02)07948-5
24. Cao L, Chen S, Zou C, Ding X, Gao L, Liao Z, et al. A pilot study of the SARC-F scale on screening sarcopenia and physical disability in the Chinese older...
people. *J Nutr Health Aging.* (2014) 18:277–83. doi: 10.1007/s12603-013-0410-3

25. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. *J Cachexia Sarcopenia Muscle.* (2016) 7:28–36. doi: 10.1002/jcsm.12048

26. Ida S, Murata K, Nakadachi D, Ishihara Y, Imataka K, Uchida A, et al. Development of a Japanese version of the SARC-F for diabetic patients: an examination of reliability and validity. *Aging Clin Exp Res.* (2017) 29:935–42. doi: 10.1007/s40520-016-0668-5

27. Mazocco L, Chagas P, Barbosa-Silva TG, Gonzalez MC, Schwanke CHA. Accuracy of SARC-F and SARC-CalF for sarcopenia screening in older women from southern Brazil. *Nutrition.* (2020) 79–80:110955. doi: 10.1016/j.nut.2020.110955

28. da Luz MCL, Pinho CPS, Bezerra GKA, da Conceicao Chaves de Lemos M, da Silva Diniz A, Cabral PC. SARC-F and SARC-CalF in screening for sarcopenia in older adults with Parkinson's disease. *Exp Gerontol.* (2021) 144:111183. doi: 10.1016/j.exger.2020.111183

29. Kawakami R, Murakami H, Tanaka K, Sawada S, Tabata I, et al. Calf circumference as a surrogate marker of muscle mass for diagnosing sarcopenia in Japanese men and women. *Geriatr Gerontol Int.* (2015) 15:969–76. doi: 10.1111/ggi.12377

30. Kim MJ, Yabushita N, Tanaka K. Exploring effective items of physical function in slow walking speed and self-reported mobility limitation in community-dwelling older adults. *Geriatr Gerontol Int.* (2012) 12:50–8. doi: 10.1111/j.1447-0594.2011.00726.x

31. Mo YH, Zhong J, Dong X, Su YD, Deng WY, Yao XM, et al. Comparison of three screening methods for sarcopenia in community-dwelling older persons. *J Am Med Dir Assoc.* (2021) 22:746–50.e1. doi: 10.1016/j.jamda.2020.05.041

32. Mohd Nawi SN, Khow KS, Lim WS, Yu SC. Screening tools for sarcopenia in community-dwellers: a scoping review. *Ann Acad Med Singap.* (2019) 48:201–16.

33. Bahat G, Tufan A, Tufan F, Kilic C, Alpınar TS, Kose M, et al. Cut-off points to identify sarcopenia according to European working group on sarcopenia in older people (EWGSOP) definition. *Clin Nutr.* (2016) 35:1557–63. doi: 10.1016/j.clnu.2016.02.002

34. Lim JY, Low NA, Merchant RA. Prevalence of sarcopenia in pre-frail community dwelling older adult and utility of SARC-F- SARC-CalF and calf circumference in case finding. *J Frutile Sarcopenia Falls.* (2020) 5:53–6. doi: 10.22540/JFSF-05-053

35. Chen CY, Tseng WC, Yang YH, Chen CL, Lin LL, Chen FP, et al. Calf circumference as an optimal choice of four screening tools for sarcopenia among ethnic Chinese older adults in assisted living. *Clin Interv Aging.* (2020) 15:2415–22. doi: 10.2147/CIA.S287207

36. Rossi AP, Micciolo R, Rubele S, Fantin F, Caliari C, Zoico E, et al. Assessing the risk of sarcopenia in the elderly: the mini sarcopenia risk assessment (MSRA) questionnaire. *J Nutr Health Aging.* (2017) 21:743–9. doi: 10.1007/s12603-017-0921-4

37. Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al. Comparing mini sarcopenia risk assessment with SARC-F for screening sarcopenia in community-dwelling older adults. *J Am Med Dir Assoc.* (2019) 20:53–7. doi: 10.1016/j.jamda.2018.04.012

38. Kurita N, Wakita T, Kamitani T, Wada O, Mizuno K. SARC-F validation and SARC-F+EBM derivation in musculoskeletal disease: the SPSS-OK study. *J Nutr Health Aging.* (2019) 23:732–8. doi: 10.1007/s12603-019-1222-x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xu, Zhang, Chen, Jiang, Zhou and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.